Non-Invasive Nasal Discharge Fluid and Other Body Fluid Biomarkers in Alzheimer's Disease
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Jung, Da Hae | - |
dc.contributor.author | Son, Gowoon | - |
dc.contributor.author | Kwon, Oh-Hoon | - |
dc.contributor.author | Chang, Keun-A | - |
dc.contributor.author | Moon, Cheil | - |
dc.date.accessioned | 2022-09-20T04:40:04Z | - |
dc.date.available | 2022-09-20T04:40:04Z | - |
dc.date.created | 2022-09-20 | - |
dc.date.issued | 2022-08 | - |
dc.identifier.issn | 1999-4923 | - |
dc.identifier.uri | https://scholarworks.bwise.kr/gachon/handle/2020.sw.gachon/85478 | - |
dc.description.abstract | The key to current Alzheimer's disease (AD) therapy is the early diagnosis for prompt intervention, since available treatments only slow the disease progression. Therefore, this lack of promising therapies has called for diagnostic screening tests to identify those likely to develop full-blown AD. Recent AD diagnosis guidelines incorporated core biomarker analyses into criteria, including amyloid-beta (A beta), total-tau (T-tau), and phosphorylated tau (P-tau). Though effective, the accessibility of screening tests involving conventional cerebrospinal fluid (CSF)- and blood-based analyses is often hindered by the invasiveness and high cost. In an attempt to overcome these shortcomings, biomarker profiling research using non-invasive body fluid has shown the potential to capture the pathological changes in the patients' bodies. These novel non-invasive body fluid biomarkers for AD have emerged as diagnostic and pathological targets. Here, we review the potential peripheral biomarkers, including non-invasive peripheral body fluids of nasal discharge, tear, saliva, and urine for AD. | - |
dc.language | 영어 | - |
dc.language.iso | en | - |
dc.publisher | MDPI | - |
dc.relation.isPartOf | PHARMACEUTICS | - |
dc.title | Non-Invasive Nasal Discharge Fluid and Other Body Fluid Biomarkers in Alzheimer's Disease | - |
dc.type | Article | - |
dc.type.rims | ART | - |
dc.description.journalClass | 1 | - |
dc.identifier.wosid | 000845721500001 | - |
dc.identifier.doi | 10.3390/pharmaceutics14081532 | - |
dc.identifier.bibliographicCitation | PHARMACEUTICS, v.14, no.8 | - |
dc.description.isOpenAccess | Y | - |
dc.identifier.scopusid | 2-s2.0-85137393654 | - |
dc.citation.title | PHARMACEUTICS | - |
dc.citation.volume | 14 | - |
dc.citation.number | 8 | - |
dc.contributor.affiliatedAuthor | Chang, Keun-A | - |
dc.type.docType | Review | - |
dc.subject.keywordAuthor | Alzheimer&apos | - |
dc.subject.keywordAuthor | s disease | - |
dc.subject.keywordAuthor | nasal discharge fluid | - |
dc.subject.keywordAuthor | body fluid | - |
dc.subject.keywordAuthor | biomarker | - |
dc.subject.keywordAuthor | diagnosis | - |
dc.subject.keywordAuthor | non-invasive | - |
dc.subject.keywordAuthor | peripheral | - |
dc.subject.keywordPlus | MILD COGNITIVE IMPAIRMENT | - |
dc.subject.keywordPlus | BLOOD-BRAIN-BARRIER | - |
dc.subject.keywordPlus | CEREBROSPINAL-FLUID | - |
dc.subject.keywordPlus | AMYLOID-BETA | - |
dc.subject.keywordPlus | SALIVARY ACETYLCHOLINESTERASE | - |
dc.subject.keywordPlus | ASSOCIATION WORKGROUPS | - |
dc.subject.keywordPlus | DIAGNOSTIC GUIDELINES | - |
dc.subject.keywordPlus | OLFACTORY DYSFUNCTION | - |
dc.subject.keywordPlus | NATIONAL INSTITUTE | - |
dc.subject.keywordPlus | PROTEOME ANALYSIS | - |
dc.relation.journalResearchArea | Pharmacology & Pharmacy | - |
dc.relation.journalWebOfScienceCategory | Pharmacology & Pharmacy | - |
dc.description.journalRegisteredClass | scie | - |
dc.description.journalRegisteredClass | scopus | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
1342, Seongnam-daero, Sujeong-gu, Seongnam-si, Gyeonggi-do, Republic of Korea(13120)031-750-5114
COPYRIGHT 2020 Gachon University All Rights Reserved.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.